Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-08-17
2001-03-06
Goldberg, Jerome D. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S336000
Reexamination Certificate
active
06197796
ABSTRACT:
TECHNICAL FIELD
The present invention relates to an anticancer composition comprising a diaminotrifluoromethylpyridine derivative or its pharmaceutically acceptable salt, as an active ingredient.
BACKGROUND ART
EP0465913-A discloses that a diaminotrifluoromethylpyridine derivative or its salt has a phospholipase A
2
inhibition activity and thus is useful as an active ingredient of an anti-inflammatory agent or an anti-pancreatitis agent. Further, the same publication discloses that in platelets or cells related to inflammatory symptoms, phospholipase A
2
is secreted or activated by various stimulations and contributes to the production of a platelet activating factor (PAF) or some arachidonic acid methabolites, and that the arachidonic acid methabolites have been found to be closely related to various diseases, for example, inflammatory symptoms such as rheumatoid arthritis, arthritis deformans, tenontitis, psoriasis and related dermatitis; nasal and bronchial airway troubles such as allergic rhinitis and allergic bronchial asthma; and immediate hypersensitive reactions such as allergic conjunctivitis. On the other hand, it is disclosed that phospholipase A
2
secreted from pancreas is activated in the intestine and exhibits a digestive action, but once activated in the pancreas, it is believed to be one of the factors causing pancreatitis. And, it is disclosed that the above diaminotrifluoromethylpyridine derivative or its salt inhibits phospholipase A
2
and thus is effective for the treatment of the above-mentioned diseases caused by phospholipase A
2
such as inflammatory symptoms, nasal and bronchial airway troubles, immediate hypersensitive reactions or pancreatitis. Thus, it is disclosed to be useful as an anti-inflammatory agent, an agent for treating bronchial asthma, an anti-allergy agent, an anti-pancreatitis agent, anti-nephritis agent, or anti-MOF (Multiple Organ Failure).
DISCLOSURE OF THE INVENTION
It is an object of the present invention to provide an anticancer composition comprising a diaminotrifluoromethylpyridine derivative or its pharmaceutically acceptable salt, as an active ingredient.
The present inventors have conducted various studies on the pharmacological activities of the diaminotrifluoromethylpyridine derivative or its salt. As a result, they have found that such a compound has a suppressive effect of carcinogenesis useful as an anticancer agent. The present invention has been accomplished on the basis of this discovery.
That is, the present invention provides an anticancer composition comprising a diaminotrifluoromethylpyridine derivative of the formula (I) or its pharmaceutically acceptable salt, as an active ingredient:
wherein X is a cycloalkylcarbonyl group, a furancarbonyl group or a benzoyl group which may be substituted by a halogen atom, and Y is an alkylsulfonyl group.
Now, the present invention will be described in detail with reference to the preferred embodiments.
The cycloalkylcarbonyl group for X in the diaminotrifluoromethylpyridine derivative of the formula (I) may be one wherein the cycloalkyl moiety has from 5 to 8 carbon atoms, such as cyclopentylcarbonyl, cyclohexylcarbonyl, cycloheptylcarbonyl or cyclooctylcarbonyl. The halogen atom as the substituent on the benzoyl group for X, may be fluorine, chlorine, bromine or iodine. The alkylsulfonyl group for Y may be one wherein the alkyl moiety has from 1 to 18 carbon atoms, such as methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, pentylsulfonyl, hexylsulfonyl, heptylsulfonyl, octylsulfonyl, decylsulfonyl or nonadecylsulfonyl, and such an alkyl moiety may be of a straight chain structure or a branched chain structure.
The salt of the diaminotrifluoromethylpyridine derivative may be any salt so long as it is a pharmaceutically acceptable salt. For example, an alkali metal salt such as a potassium salt or a sodium salt, an alkaline earth metal salt such as a calcium salt, or an organic amine salt such as a triethanolamine salt or a tris(hydroxymethyl)aminomethane salt may be mentioned. Among such salts, some may have crystal water.
Specific examples of the diaminotrifluoromethylpyridine derivative of the formula (I) or its salt, include N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclohexane-carboxamide or its sodium salt, N-(2-isopropylsulfonylamino-5-trifluoromethyl-3-pyridyl) cyclopentane-carboxamide, N-(2-methylsulfonylamino-5-trifluoromethyl-3-pyridyl)-2-furancarboxamide, N-(2-methylsulfonylamino-5-trifluromethyl-3-pyridyl)-4-fluorobenzamide, and N-(2-isopropylsulfonylamino-5-trifluoromethyl-3-pyridyl)-3-fluorobenzamide.
The diaminotrifluoromethylpyridine derivative or its pharmaceutically acceptable salt is useful as an active ingredient of an anticancer composition. Particularly, such a compound has a suppressive effect of carcinogenesis and is effective, for example, for suppressing multiple carcinogenesis after removal of solid tumor. Such multiple carcinogenesis may take place in a case of e.g. superficial bladder cancer, hepatic cancer or lung cancer, and the compound suppresses relapse of such a cancer after removal of the solid tumor. The relapse process after removal of the solid cancer includes a phenomenon such as invasion or implantation of cancer cells released by the removal to the surrounding tissues (so-called tumor metastasis). Such a compound has been found to have an inhibitory activity against cell adhesion and cell infiltration, as one of its activities. Thus, such a compound is expected to be effective also for suppressing tumor metastasis. Further, such a compound suppresses a progress from colic polypus to colon cancer, or a progress from hyperplasia by papilloma virus to uterine cervix cancer.
To administer the diaminotrifluoromethylpyridine derivative or its salt as an active ingredient of an anticancer composition, it is formulated alone or together with a pharmaceutically acceptable carrier into a drug composition suitable for peroral, or parenteral administration, such as a tablet, a powder, a capsule, a granule, an injection drug, an ointment, an inhalant or a suppository, and it is administered in the form of such a drug formulation.
As a drug formulation suitable for peroral administration, a solid composition such as a tablet, a capsule, a powder, a granule or a troach; or a liquid composition such as a syrup suspension, may be mentioned. The solid composition such as a tablet, a capsule, a powder, a granule or a troach may contain a binder such as fine crystalline cellulose, gum arabic, tragacanth gum, gelatin or polyvinyl pyrrolidone; an excipient such as starch, lactose or carboxymethyl cellulose; a disintegrator such as alginic acid, corn starch or carboxymethyl cellulose; a lubricant such as magnesium stearate, light silicic anhydride or colloidal silicon dioxide; a sweetener such as sucrose; or a flavoring agent such as peppermint or methyl salicylate. The liquid composition such as a syrup or a suspension may contain sorbitol, gelatin, methyl cellulose, carboxymethyl cellulose, a vegetable oil such as a peanut oil, an emulsifier such as lecithin as well as a sweetener, a preservative, a colorant or a flavoring agent, as the case requires. Such a composition may be provided in the form of a dried formulation. These formulations may contain from 1 to 95% by weight of the active compound.
A drug formulation suitable for parenteral administration may, for example, be an injection drug, an inhalant, an ointment or a suppository. The injection drug may be prepared by dissolving the compound in the form of a salt in usual water for injection, or may be formulated into a formulation suitable for injection such as a suspension or an emulsion (in a mixture with a pharmaceutically acceptable oil or liquid). In such a case, it may contain benzyl alcohol as an antibacterial agent, ascorbic acid as an antioxidant, a pharmaceutically acceptable buffer solution or a reagent for adjusting the osmotic pressure. Such an injection drug preferably contains from 0.1 to 50% by weight of the active compound.
The inhalant may be formulate
Goldberg Jerome D.
Ishihara Sangyo Kaisha Ltd.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Anticancer composition comprising a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticancer composition comprising a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticancer composition comprising a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2500649